Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Otsuka to Focus on CNS Field, Ending Collaboration in Immunology, Inflammation with UCB
January 16, 2012
- With 3 New Treatments, 2011 a Big Year for Domestic AD Market
January 15, 2012
- Nichi-Iko Posts Record-High Sales, Profits in FY2011
January 13, 2012
- Pfizer to Strengthen Role of Manufacturing Division by Spin-Off, Utilizing Its Formulation Technology
January 13, 2012
- Hisamitsu: Sales Up 1.2% Due to Favorable Performance of Overseas Subsidiaries
January 13, 2012
- Major Dispensing Pharmacies, Intermediary Companies Aggressively Seek M&A
January 12, 2012
- Survey Shows Astellas Website Most Frequently Accessed by Doctors
January 12, 2012
- Barclays Capital Report Mentions Tivozanib, Raises Astellas Pharma’s Target Stock Price
January 12, 2012
- Interprotein, Takeda Sign Collaboration Agreement on Molecular Design for PPI Modulators
January 12, 2012
- Sales of Ethical Drugs Up 5.2% in November: Crecon Report
January 12, 2012
- Administration of OTSA101 Started in Trial for Synovial Sarcoma: OncoTherapy
January 12, 2012
- Dispensing Point Services Should Continue: Mr Arai of Sugi HD
January 12, 2012
- Current Pollinosis Treatments Least Effective at Relieving Nasal Congestion: MSD
January 12, 2012
- Kyowa Kirin President Matsuda Aims for Global Presence in Biosimilar Business
January 11, 2012
- DSP to Change Brand Name of Almarl to Avoid Confusion
January 11, 2012
- Kyowa Hakko Kirin to Develop Expert MRs to Boost Cancer Field
January 11, 2012
- Nipro to Set Up Pharmaceutical Plant in Vietnam for Contract Manufacturing of Generics
January 11, 2012
- Bayer Submits Rivaroxaban in EU, US for Add’l Indication
January 11, 2012
- Interprotein, Takeda to Collaborate on Molecular Designing of PPI Modulators
January 11, 2012
- Observation Period Ended in PII/III Trial of Elpamotide: OncoTherapy
January 11, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…